Literature DB >> 15067194

Regulation of CX3CL1/fractalkine expression in endothelial cells.

Tadaatsu Imaizumi1, Hidemi Yoshida, Kei Satoh.   

Abstract

CX3CL1/fractalkine is a chemokine with a unique CX3C motif. Fractalkine is synthesized in endothelial cells as a membrane protein, and the N-terminal domain containing a CX3C motif is cleaved and secreted. CX3CR1, the specific receptor for fractalkine, is expressed in monocytes and lymphocytes. Membrane-bound fractalkine works as an adhesion molecule for these leukocytes and the secreted form as a chemotactic factor. Fractalkine is produced by endothelial cells stimulated with tumor necrosis factor-alpha, interleukin-1 (IL-1), lipopolysaccharide and interferon-gamma. Expression of fractalkine in endothelial cells is inhibited by the soluble form of IL-6 receptor-alpha, 15-deoxy-Delta(12,14)-prostaglandin J(2), and hypoxia. The expression of fractalkine is tightly regulated and fractalkine plays an important role in the interaction between leukocytes and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067194     DOI: 10.5551/jat.11.15

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  51 in total

1.  Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages.

Authors:  Michael Miksa; Dhruv Amin; Rongqian Wu; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

2.  Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis.

Authors:  Hale Gokcan; Erkan Yurtcu; Haldun Selcuk; Feride I Sahin
Journal:  Bosn J Basic Med Sci       Date:  2015-05-25       Impact factor: 3.363

Review 3.  Inflammation and the blood microvascular system.

Authors:  Jordan S Pober; William C Sessa
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-10-23       Impact factor: 10.005

4.  The HCMV US28 vGPCR induces potent Gαq/PLC-β signaling in monocytes leading to increased adhesion to endothelial cells.

Authors:  Shu-En Wu; William E Miller
Journal:  Virology       Date:  2016-08-04       Impact factor: 3.616

5.  Silencing CX3CR1 production modulates the interaction between dendritic and endothelial cells.

Authors:  Xiaoyan Liu; Guohong Lu; Jinfang Shen
Journal:  Mol Biol Rep       Date:  2010-04-03       Impact factor: 2.316

6.  Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.

Authors:  Miquel Sans; Silvio Danese; Carol de la Motte; Heitor S P de Souza; Brenda M Rivera-Reyes; Gail A West; Manijeh Phillips; Jeffry A Katz; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2006-10-12       Impact factor: 22.682

7.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

8.  IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors.

Authors:  Soo Hyun Ahn; Andrew K Edwards; Sukhbir S Singh; Steven L Young; Bruce A Lessey; Chandrakant Tayade
Journal:  J Immunol       Date:  2015-08-10       Impact factor: 5.422

9.  Hypoxia-induced endothelial CX3CL1 triggers lung smooth muscle cell phenotypic switching and proliferative expansion.

Authors:  Jianliang Zhang; Hanbo Hu; Nadia L Palma; Jeffrey K Harrison; Kamal K Mubarak; Robin D Carrie; Hassan Alnuaimat; Xiaoqiang Shen; Defang Luo; Jawaharlal M Patel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-09-21       Impact factor: 5.464

10.  CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes.

Authors:  Anna Corcione; Elisa Ferretti; Maria Bertolotto; Franco Fais; Lizzia Raffaghello; Andrea Gregorio; Claudya Tenca; Luciano Ottonello; Claudio Gambini; Glaucia Furtado; Sergio Lira; Vito Pistoia
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.